CCR2 and neoplasm: The combination with CCR2 inhibitor PF-04136309 and FOLFIRINOX chemotherapy to treat tumors in a phase Ib trial (NCT01413022) to achieve an objective tumor response, with local tumor control achieved in most patients (185), which suggest that inhibition of CCR2 can improve the effect of tumor chemotherapy.